Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Lexicon Pharmaceuticals, Inc. - Common Stock (NQ:LXRX)

1.695 -0.065 (-3.69%)

Streaming Delayed Price Updated: 1:05 PM EST, Jan 23, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	2,310,897
Open	1.780
Bid (Size)	1.690 (8,600)
Ask (Size)	1.700 (11,800)
Prev. Close	1.760
Today's Range	1.650 - 1.789
52wk Range	0.2836 - 1.830
Shares Outstanding	144,474,452
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary

Today 8:30 EST

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain

January 21, 2026

– No objections raised by FDA to advancement of pilavapadin into Phase 3 development utilizing two-arm registrational studies of 10 mg daily dose compared to placebo –

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Performance

YTD	+48.7%	+48.7%
1 Month	+40.1%	+40.1%
3 Month	+21.1%	+21.1%
6 Month	+50.0%	+50.0%
1 Year	+101.8%	+101.8%

More News

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference

January 12, 2026

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Lexicon Pharmaceuticals Publishes “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain”

January 09, 2026

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 07, 2026

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Get insights into the top gainers and losers of Wednesday's pre-market session. ↗

December 31, 2025

Via Chartmill

Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851

December 10, 2025

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum

December 05, 2025

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences

November 25, 2025

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Xpeng, Dell And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

November 17, 2025

Via Benzinga

Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference

November 11, 2025

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025

November 08, 2025

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) Q3 2025 Earnings Surpass Expectations, Fueling Pre-Market Rally ↗

November 06, 2025

Via Chartmill

Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates

November 06, 2025

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Data Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient Populations will be Presented at the Hypertrophic Cardiomyopathy Society and American Heart Association’s Sessions 2025 in New Orleans

November 04, 2025

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

October 30, 2025

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit

October 14, 2025

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain

October 08, 2025

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Inventiva, MoonLake Immunotherapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

September 29, 2025

Via Benzinga

Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes

September 22, 2025

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings

September 17, 2025

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings

September 11, 2025

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes

September 08, 2025

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025

September 04, 2025

From Lexicon Pharmaceuticals, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Lexicon Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, Lexicon Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does Lexicon Pharmaceuticals, Inc. - Common Stock trade on?

Lexicon Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Lexicon Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for Lexicon Pharmaceuticals, Inc. - Common Stock is LXRX on the Nasdaq Stock Market

What is the current price of Lexicon Pharmaceuticals, Inc. - Common Stock?

The current price of Lexicon Pharmaceuticals, Inc. - Common Stock is 1.695

When was Lexicon Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of Lexicon Pharmaceuticals, Inc. - Common Stock was at 01/23/26 01:05 PM ET

What is the market capitalization of Lexicon Pharmaceuticals, Inc. - Common Stock?

The market capitalization of Lexicon Pharmaceuticals, Inc. - Common Stock is 244.88M

How many shares of Lexicon Pharmaceuticals, Inc. - Common Stock are outstanding?

Lexicon Pharmaceuticals, Inc. - Common Stock has 245M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.